Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 7Venous Thromboembolism 3Venous Thrombosis 2Thrombosis 2Thromboembolism 2Pulmonary Embolism 2Prostatic Neoplasms 2Urinary Tract Infections 1Unspecified Adult Solid Tumor, Protocol Specific 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Sarcoma, Alveolar Soft Part 1Retinitis 1Renal Insufficiency, Chronic 1Pulmonary Arterial Hypertension 1Prostate Cancer Patients 1Pneumonia 1Pharmacokinetics of MDV3100 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Neutropenia 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Myeloma 1

Interventions

ceritinib 1Warfarin 1Midazolam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ALK-positive Advanced Tumors × Warfarin × Clear all
NCT02422589 2020-12-19

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Novartis

Phase 1 Completed
33 enrolled

ALK-positive Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡